Cargando…
The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma
BACKGROUND: B cell maturation antigen (BCMA) targeted immunotherapies have demonstrated remarkable clinical efficacy in multiple myeloma (MM). Here, we evaluated the BCMA expression in MM and other plasma cell dyscrasias (PCDs), hoping to provide a potential treatment strategy for the relapsed/refra...
Autores principales: | Xu, Yanjie, Mao, Xia, Que, Yimei, Xu, Menglei, Li, Chunhui, Almeida, Varlene Daniela Fernandes, Wang, Di, Li, Chunrui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903528/ https://www.ncbi.nlm.nih.gov/pubmed/36750969 http://dx.doi.org/10.1186/s12885-023-10591-1 |
Ejemplares similares
-
Mutations in immunodeficiency-related genes may increase the risk of infection after CAR-T-cell therapy: a report of two cases
por: Wang, Di, et al.
Publicado: (2023) -
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials
por: Que, Yimei, et al.
Publicado: (2021) -
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
por: Xu, Jinhuan, et al.
Publicado: (2018) -
Telomerase activity in plasma cell dyscrasias
por: Xu, D, et al.
Publicado: (2001) -
Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)